• Explore /
  • Poster
  • / A phase I trial of ipilimumab (ipi) in patients (pts) with myelodysplastic syndromes (MDS) after hypomethylating agent (HMAs) failure.

A phase I trial of ipilimumab (ipi) in patients (pts) with myelodysplastic syndromes (MDS) after hypomethylating agent (HMAs) failure.

Abstract Poster

Authors

null

Amer M Zeidan

Yale School of Medicine, New Haven, CT

Amer M Zeidan , Hanna Knaus , Tara M. Robinson , Joshua F. Zeidner , Amanda L. Blackford , David Rizzieri , Mark G. Frattini , Moshe Yair Levy , Mark A. Schroeder , Anna K. Ferguson , Katherine Sheldon , Amy Elizabeth Dezern , Ivana Gojo , Steven Gore , Howard Streicher , Leo Luznik , Amy Duffield , B. Douglas Smith

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Myelodysplastic Syndromes (MDS)

Clinical Trial Registration Number

NCT01757639

Citation

J Clin Oncol 35, 2017 (suppl; abstr 7010)

DOI

10.1200/JCO.2017.35.15_suppl.7010

Abstract #

7010

Poster Bd #

210

Abstract Disclosures

Similar Posters

First Author: Guillermo De Velasco

First Author: Mehmet Akce

First Author: Takayuki Nakayama

First Author: Tuba Nur Gide